scholarly journals International Committee for Monitoring Assisted Reproductive Technologies world report: assisted reproductive technology 2012†

2020 ◽  
Vol 35 (8) ◽  
pp. 1900-1913 ◽  
Author(s):  
Jacques de Mouzon ◽  
Georgina M Chambers ◽  
Fernando Zegers-Hochschild ◽  
Ragaa Mansour ◽  
Osamu Ishihara ◽  
...  

Abstract STUDY QUESTION What was the utilization, effectiveness and safety of practices in ART globally in 2012 and what global trends could be observed? SUMMARY ANSWER The total number of ART cycles increased by almost 20% since 2011 and the main trends were an increase in frozen embryo transfers (FET), oocyte donation, preimplantation genetic testing and single embryo transfers (SET), whereas pregnancy and delivery rates (PR, DR) remained stable, and multiple deliveries decreased. WHAT IS KNOWN ALREADY ART is widely practiced throughout the world, but continues to be characterized by significant disparities in utilization, availability, practice, effectiveness and safety. The International Committee for Monitoring Assisted Reproductive Technologies (ICMART) annual world report provides a major tool for tracking trends in ART treatment for over 25 years and gives important data to ART professionals, public health authorities, patients and the general public. STUDY DESIGN, SIZE, DURATION A retrospective, cross-sectional survey on the utilization, effectiveness and safety of ART procedures performed globally during 2012 was carried out. PARTICIPANTS/MATERIALS, SETTING, METHODS Sixty-nine countries and 2600 ART clinics submitted data on ART cycles performed during the year 2012, and their pregnancy outcome, through national and regional ART registries. ART cycles and outcomes are described at country, regional and global levels. Aggregate country data were processed and analyzed based on methods developed by ICMART. MAIN RESULTS AND ROLE OF CHANCE A total of 1 149 817 ART cycles were reported for the treatment year 2012. After imputing data for missing values and non-reporting clinics in reporting countries, 1 948 898 cycles (an increase of 18.6% from 2011) resulted in >465 286 babies (+17.9%) in reporting countries. China did not report and is not included in this estimate. The best estimate of global utilization including China is ∼2.8 million cycles and 0.9 million babies. From 2011 to 2012, the number of reported aspirations and FET cycles increased by 6.9% and 16.0%, respectively. The proportion of women aged 40 years or older undergoing non-donor ART increased from 24.0% in 2011 to 25.2% in 2012. ICSI, as a percentage of non-donor aspiration cycles, increased from 66.5% in 2011 to 68.9% in 2012. The IVF/ICSI combined delivery rates per fresh aspiration and FET cycles were 19.8% and 22.1%, respectively. In fresh non-donor cycles, SET increased from 31.4% in 2011 to 33.7% in 2012, while the average number of transferred embryos decreased from 1.91 to 1.88, respectively—but with wide country variation. The rates of twin deliveries following fresh non-donor transfers decreased from 19.6% in 2011 to 18.0% in 2012, and the triplet rate decreased from 0.9% to 0.8%. In FET non-donor cycles, SET was 54.8%, with an average of 1.54 embryos transferred and twin and triplet rates of 11.1% and 0.4%, respectively. The cumulative DR per aspiration increased from 28.0% in 2011 to 28.9% in 2012. The overall perinatal mortality rate per 1000 births was 21.4 following fresh IVF/ICSI and 15.9 per 1000 following FET. LIMITATIONS, REASONS FOR CAUTION The data presented depend on the quality and completeness of data submitted by individual countries to ICMART directly or through regional registries. This report covers approximately two-thirds of` world ART activity, with a major missing country, China. Continued efforts to improve the quality and consistency of reporting ART data by registries are still needed, including the use of internationally agreed standard definitions (International Glossary of Infertility and Fertility Care). WIDER IMPLICATIONS OF THE FINDINGS The ICMART world reports provide the most comprehensive global statistical census and review of ART utilization, effectiveness, safety and quality. While ART treatment continues to increase globally, the wide disparities in access to treatment, procedures performed and embryo transfer practices warrant attention by clinicians and policy makers. With the increasing practice of SET and of freeze all and resulting increased proportion of FET cycles, it is clear that PR and DR per aspiration in fresh cycles do not give an overall accurate estimation of ART efficiency. It is time to use cumulative live birth rate per aspiration, combining the outcomes of FET cycles with the associated fresh cycle from which the embryos were obtained, and to obtain global consensus on this approach. STUDY FUNDING/COMPETING INTEREST(S) The authors declare no conflict of interest and no specific support from any organizations in relation to this manuscript. ICMART gratefully acknowledges financial support from the following organizations: American Society for Reproductive Medicine; European Society for Human Reproduction and Embryology; Fertility Society of Australia; Japan Society for Reproductive Medicine; Japan Society of Fertilization and Implantation; Red Latinoamericana de Reproduccion Asistida; Society for Assisted Reproductive Technology; Ferring Pharmaceuticals and Abbott (both providing ICMART unrestricted grants unrelated to world reports). TRIAL REGISTRATION NUMBER NA.

Author(s):  
Raquel Taranilla

Resumen: Este artículo comienza abordando el discurso producido en torno a la tecnología de la reproducción asistida. A partir de los textos emitidos por la clínica de fertilidad, se pretende comprender el papel actual de los tratamientos reproductivos y plantear, yendo más allá de las críticas que generan, en qué han ayudado a derribar estereotipos muy establecidos. En primer lugar, la generalización de las tecnologías de reproducción asistida ha acabado con el relato hegemónico sobre la concepción humana (en el que un espermatozoide poderoso logra conquistar un óvulo e iniciar una vida nueva). En segundo lugar, la clínica de fertilidad obliga a entender la reproducción humana como una tarea colectiva, en la que se generan relaciones fructíferas. En tercer lugar, también hace emerger nuevas subjetividades ligadas a la maternidad/paternidad y la filiación, que consiguen desestabilizar ciertas identidades de género y de familia que han sido privilegiadas hasta ahora. A modo de ejemplo de nueva subjetividad, se propone la maternidad jubilea, en cuya fusión de cuerpo y tecnología queda cuestionada con éxito la construcción social de la esterilidad. Palabras clave: clínica de fertilidad, tecnología de reproducción asistida, maternidad, filiación, subjetividad, discurso de la medicina. Abstract: This article addresses the discourse of assisted reproduction technology. By analyzing texts produced by fertility clinics, the aim is to describe the current role of reproductive treatments and to consider their benefits in undermining well-established stereotypes. First, the increase in the use of assisted reproductive technologies breaks down the hegemonic narrative of human conception (in which the powerful sperm conquers the egg to start a new life). Second, in fertility clinic human reproduction should be considered a collective task, in which fruitful relationships are developed. Third, assisted reproductive technology fosters the emergence of new subjectivities linked to motherhood/fatherhood and filiation, which destabilize prevailing gender and family identities. As an example of a new subjectivity, jubilee motherhood is proposed. The fusion of body and technology in it challenges the social construction of infertility. Keywords: fertility clinic, assisted reproductive technology, motherhood, filiation, subjectivity, medical discourse.


2021 ◽  
Vol 17 (1) ◽  
Author(s):  
Michael Legge ◽  
Ruth Fitzgerald

The use of assisted reproductive technologies (ART) in New Zealand is governed by the Human Assisted Reproductive Technology Act 2004 (the HART Act), which provides for all procedures currently undertaken by fertility clinics and other centres involved with ART. Although the Act has provided good coverage for the use of ART over the last 16 years, it did not have a revision clause. Here, we explore whether the HART Act should be reviewed, and outline the important considerations that need to be taken into account to ensure that the legislation is up to date with current issues and technologies.


2015 ◽  
Vol 103 (2) ◽  
pp. 402-413.e11 ◽  
Author(s):  
Osamu Ishihara ◽  
G. David Adamson ◽  
Silke Dyer ◽  
Jacques de Mouzon ◽  
Karl G. Nygren ◽  
...  

Author(s):  
Ayo Wahlberg

This chapter chronicles the difficult birth of assisted reproductive technologies (ARTs) in China through the 1980s and 1990s, showing how ideas of improving population quality acted as a persuasive alibi for those pioneers working to develop fertility technologies under crude conditions and at a time when contraception rather than conception was at the core of family planning. From difficult beginnings in the 1980s and following legalization in 2003, ARTs have now settled firmly within China’s restrictive reproductive complex as technologies of birth control—which, in turn, has allowed it to grow into a thriving, sector as China is now home to some of the world’s largest fertility clinics and sperm banks.


Sign in / Sign up

Export Citation Format

Share Document